Non Alcoholic Fatty Liver Disease (NAFLD) and NonAlcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 provides an overview of the pipeline for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The report provides comprehensive information on the therapeutics under development and key players active in this space, and features dormant and discontinued projects.
Both NASH and NAFLD occur largely as a result of prolonged insulin resistance and obesity with approximately 80% of cases being diagnosed in overweight individuals. NASH is a severe form of NAFLD and is likely to become even more of a healthcare burden than it is at present. NASH can lead to liver cirrhosis and ultimately liver failure, which can be fatal if it is not treated quickly.
There are a total of 195 pipeline products in development for NASH and 65 products in development for NAFLD. Across the therapy area there are 158 companies developing products for NASH and 57 companies developing products for NAFLD. Key companies active in this space include Gilead, Novartis and Pfizer.
Which companies are the most active within the pipeline for NAFLD and NASH therapeutics?
Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened within this field?